RIO BIOPHARMACEUTICALS, INC.

• BALLARD PARTNERS $850,000 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

• 2026 $450,000 3 filings
• 2025 $400,000 4 filings

• Pharmacy 7

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

• Health & Human Services, Dept of (HHS) 6
• Commerce, Dept of (DOC) 2
• Executive Office of the President (EOP) 2
• HOUSE OF REPRESENTATIVES 2
• SENATE 2
• White House Office 2
• Food & Drug Administration (FDA) 1

• GLOBE PHARMA S.A.R.L. Luxembourg named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0
• SALTMONT FUNDO DE INVESTIMENTO EM PARTICIPAOES MULTIESTRATEGIA INVESTIMENTO NO EXTERIOR (HOLDS 75% OF GLOBE PHARMA S.A.R.L) Brazil named on 1 filing · highest disclosed ownership 75% · largest disclosed contribution $0
• YANKEE-F FUNDO DE INVESTIMENTO MULTIMERCADO CREDITO PRIVADO INVESTIMENTO NO EXTERIOR (HOLDS 88% OF SALTMONT FIP) Brazil named on 1 filing · highest disclosed ownership 66% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.